Apellis Pharmaceuticals I... (APLS)
NASDAQ: APLS
· Real-Time Price · USD
26.04
-0.80 (-2.98%)
At close: Sep 10, 2025, 3:59 PM
26.00
-0.15%
After-hours: Sep 10, 2025, 05:30 PM EDT
Apellis Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing And Other Revenue Revenue | 7.11M | 16.9M | 21.36M | 20.26M | 20.55M | 9.25M | 7.72M | 11.22M | 5.32M | 6.05M | 3.01M | 4.38M | 668K | 2.27M | 51.08M | 336K |
| Licensing And Other Revenue Revenue Growth | -57.94% | -20.88% | +5.41% | -1.41% | +122.15% | +19.77% | -31.15% | +110.69% | -11.94% | +100.86% | -31.28% | +555.69% | -70.60% | -95.55% | +15102.38% | n/a |
| Product Revenue | 171.39M | 149.9M | 191.17M | 176.57M | 179.14M | 163.07M | 138.65M | 99.18M | 89.64M | 38.8M | 19.65M | 17.68M | 15.65M | 12.11M | 9.21M | 5.31M |
| Product Revenue Growth | +14.33% | -21.59% | +8.27% | -1.43% | +9.85% | +17.61% | +39.80% | +10.64% | +131.04% | +97.43% | +11.18% | +12.92% | +29.28% | +31.48% | +73.32% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 130.69M | 129.34M | 121.48M | 121.98M | 127.63M | 129.06M | 141.7M | 145.65M | 111.37M | 102.09M | 84.37M | 78.41M | 63.2M | 51.19M | 41.46M | 45.76M | 48.97M | 40.58M | 44.49M | 36.99M | 28.41M | 29.5M | 27.47M | 18.63M | 12.78M | 8.17M | 6.39M | 6.26M | 5.95M | 4.04M | 4.86M | 2.07M | 1.71M | 1.82M | 1.09M | 1M | 1.11M | 1.11M | 3.04M | 1.41M | 950.66K | 950.66K |
| Selling, General, and Administrative Revenue Growth | +1.04% | +6.47% | -0.41% | -4.43% | -1.11% | -8.92% | -2.71% | +30.77% | +9.09% | +21.01% | +7.60% | +24.05% | +23.47% | +23.46% | -9.40% | -6.54% | +20.67% | -8.79% | +20.28% | +30.19% | -3.69% | +7.41% | +47.45% | +45.79% | +56.38% | +27.85% | +2.01% | +5.33% | +47.41% | -16.98% | +134.67% | +21.11% | -6.10% | +67.53% | +8.70% | -9.75% | 0.00% | -63.59% | +115.36% | +48.63% | 0.00% | n/a |
| Research and Development Revenue | 67.02M | 86.42M | 76.35M | 88.57M | 77.95M | 84.7M | 69.28M | 79.42M | 95.66M | 110.03M | 99.42M | 95.21M | 101.66M | 90.94M | 108.18M | 87.73M | 145.94M | 84.01M | 50.34M | 93.21M | 87.09M | 69.28M | 78.47M | 51.32M | 50.7M | 40.48M | 30.81M | 29.54M | 27.54M | 17.4M | 13.13M | 9.52M | 10.42M | 7.23M | 5.59M | 6.23M | 5.58M | 5.58M | 3.93M | 3.75M | 3.03M | 3.03M |
| Research and Development Revenue Growth | -22.45% | +13.18% | -13.79% | +13.63% | -7.97% | +22.26% | -12.77% | -16.97% | -13.06% | +10.67% | +4.43% | -6.35% | +11.78% | -15.93% | +23.31% | -39.89% | +73.72% | +66.90% | -45.99% | +7.02% | +25.71% | -11.71% | +52.91% | +1.22% | +25.24% | +31.40% | +4.29% | +7.27% | +58.24% | +32.51% | +37.98% | -8.67% | +44.13% | +29.31% | -10.30% | +11.80% | 0.00% | +41.96% | +4.89% | +23.68% | 0.00% | n/a |